U.S. SECURITIES AND EXCHANGE COMMISSION

FORM 10-Q

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2004

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number 1-14131

ALKERMES, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number including area code: (617) 494-0171

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No o

     Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes þ No o

     The number of shares outstanding of each of the issuer’s classes of common stock was:

ALKERMES, INC. AND SUBSIDIARIES

INDEX

2

PART 1. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited):

ALKERMES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

See Notes to Condensed Consolidated Financial Statements.

3

ALKERMES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

See Notes to Condensed Consolidated Financial Statements.

4

ALKERMES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

See Notes to Condensed Consolidated Financial Statements.

5

ALKERMES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements of Alkermes, Inc. (the “Company”) are unaudited and have been prepared on a basis substantially consistent with the audited financial statements. The condensed consolidated financial statements, in the opinion of management, include all adjustments which are necessary to present fairly the results of operations for the reported periods. The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting.

These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto which are contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2004, filed with the SEC.

The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Alkermes Controlled Therapeutics, Inc., Alkermes Controlled Therapeutics Inc. II (“ACT II”), Advanced Inhalation Research, Inc. (“AIR^®”), Alkermes Investments, Inc., Alkermes Europe, Ltd., Alkermes Development Corporation II (“ADCII”) and RC Royalty Sub LLC (“Royalty Sub”), wholly owned subsidiaries of the Company. Intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with GAAP necessarily requires management to make estimates and assumptions that affect the following: (1) reported amounts of assets and liabilities; (2) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (3) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Pronouncements

In December 2004, the Financial Accounting Standards Board (“FASB”) issued Statement No. 123 (revised 2004), “Share-Based Payment” (“SFAS 123R”), which requires companies to measure and recognize compensation expense for all stock-based payments at fair value. SFAS 123R is effective for all interim periods beginning after June 15, 2005 and, thus, will be effective for the Company beginning with the second quarter of fiscal 2006 (i.e. the quarter ending September 30, 2005). Early adoption is encouraged and retroactive application of the provisions of SFAS 123R to the beginning of the fiscal year that includes the effective date is permitted, but not required. The Company is currently evaluating the impact of SFAS 123R on its results of operations. See Note 4 for information related to the pro forma effects on the reported net loss and net loss per share of applying the fair value recognition provisions of the previous Statement of Financial Accounting Standards (“SFAS”) 123, “Accounting for Stock-Based Compensation,” to stock-based employee compensation.

6

In November 2004, FASB issued SFAS No. 151, “Inventory Costs”, which amends Accounting Research Bulletin (“ARB”) No. 43, Chapter 4, “Inventory Pricing,” to clarify the accounting for idle facility expense, freight, handling costs and waste (spoilage). This Statement is effective for inventory costs incurred during fiscal 2007 and earlier application is permitted. The Company believes our current accounting policies closely align to the new rules. Accordingly, the Company does not believe this new standard will have a material impact on our financial statements.

2. COMPREHENSIVE LOSS

Comprehensive loss for the three and nine months ended December 31, 2004 and 2003 is as follows:

3. NET LOSS PER COMMON SHARE

Net loss per common share is computed using the weighted-average number of common shares outstanding during the period. For the three and nine months ended December 31, 2004 and 2003, the Company was in a net loss position and, therefore, common equivalent shares are not included in the per share calculation because their effect would be anti-dilutive. As such, diluted net loss per common share is the same amount as basic net loss per common share.

The following table sets forth common stock equivalents which were excluded from the computation of diluted net loss per common share for the three and nine months ended December 31, 2004 and 2003 as they would have had an anti-dilutive effect due to net losses for such periods:

4. STOCK-BASED COMPENSATION

The Company grants stock options for a fixed number of shares to employees with an exercise price equal to the fair market value of the shares at the date of grant. The Company accounts for stock option and award grants to employees using the intrinsic value method. The Company accounts for stock options and awards to non-employees using the fair-value method.

The following table illustrates the effect on net loss and net loss per common share, basic and diluted, as if the fair-value based method had been applied to all outstanding and stock options and awards in each period. Pro forma information for the three and nine months ended December 31, 2004 and 2003 is as follows:

7

The fair value of stock options was estimated at the date of grant using the Black-Scholes option-pricing model, assuming no dividends, and with the following weighted average assumptions and the resulting weighted average fair value per share of option granted during the period:

5. RESTRUCTURINGS

In August 2002, the Company announced a restructuring program to reduce the Company’s cost structure as a result of the financial impact of a delay in the U.S. launch of Risperdal Consta by the Company’s collaborative partner, Janssen (the “2002 Restructuring”). The restructuring program reduced our workforce by 122 employees, representing 23% of the Company’s total workforce at that time, and included consolidation and closure of certain leased facilities in Cambridge, Massachusetts, closure of the Company’s medical affairs office in Cambridge, England, write-off of leasehold improvements at leased facilities being vacated and reductions of other expenses. As of December 31, 2004, the Company had paid in cash or written off an aggregate of approximately $1.6 million in employee separation costs and approximately $4.2 million in facility closure costs in connection with the 2002 Restructuring. The amounts remaining in the 2002 Restructuring accrual at December 31, 2004 related to facility lease costs and are expected to be paid through fiscal 2006.

In June 2004, the Company announced a restructuring program in connection with the decision by Alkermes and Genentech to discontinue commercialization of Nutropin Depot (the “2004 Restructuring”). The decision was based on the significant resources required by both companies to continue manufacturing and commercializing the product. In connection with this decision, the Company ceased commercial manufacturing of Nutropin Depot in June 2004, reduced the Company’s workforce by 17 employees, representing approximately 3% of the Company’s total workforce, and recorded restructuring charges in the quarter ended June 30, 2004 of approximately $11.9 million under the caption “Restructuring” in the consolidated statements of operations. The restructuring charges

8

consisted of approximately $0.2 million in employee separation costs, including severance and related benefits, and approximately $11.7 million in facility closure costs, including fixed asset write-offs and estimates of future lease costs relating to the Company’s ability to sublease the exited facility through the end of its lease term, August 2008. In addition to the restructuring charges recorded in the quarter ended June 30, 2004, the Company also recorded a one-time write-off of Nutropin Depot inventory of approximately $1.3 million, which was recorded under the caption “Cost of goods manufactured” in the consolidated statements of operations.

As of December 31, 2004, the Company had paid in cash or written off an aggregate of approximately $8.6 million in facility closure costs and $0.1 million in employee separation costs in connection with the 2004 Restructuring. The amounts remaining in the 2004 Restructuring accrual at December 31, 2004 are expected to be paid out through fiscal 2009 and relate primarily to estimates of lease costs associated with the exited facility.

The following table displays the restructuring activities and liability balances included in accrued restructuring costs:

6. INVENTORY

Inventory is stated at the lower of cost or market. Cost is determined in a manner that approximates the first-in, first-out method. The components of inventory consist of the following:

In connection with the 2004 Restructuring, the Company recorded a one-time write-off of Nutropin Depot inventory of approximately $1.3 million in the quarter ended June 30, 2004, which was recorded under the caption “Cost of goods manufactured” in the condensed consolidated statements of operations. See Note 5 for discussion on restructuring charges.

7. DERIVATIVES

2 1/2% Subordinated Notes -— In the event that an automatic conversion of the 2 1/2% Subordinated Notes due 2023 (the “2 1/2% Subordinated Notes”) occurs on or prior to September 1, 2006, the Company would be required to pay

9

additional interest in cash or, at the Company’s option in common stock, equal to three full years of interest on the converted notes (the “Three Year Interest Make-Whole”), less any interest actually paid or provided for on the notes prior to automatic conversion. This Three-Year Interest Make-Whole provision represents an embedded derivative that is required to be accounted for apart from the underlying 2 1/2% Subordinated Notes. When the 2 1/2% Subordinated Notes were issued, the Three-Year Interest Make-Whole had an estimated initial aggregate fair value of $3.9 million, which reduced the amount of the outstanding debt and was recorded as a derivative liability in the condensed consolidated balance sheets. The $3.9 million initially allocated to the Three-Year Interest Make-Whole feature has been treated as a discount on the 2 1/2% Subordinated Notes and is being accreted to interest expense over five years through September 1, 2008, the first date on which holders of the 2 1/2% Subordinated Notes have the right to require the Company to repurchase the 2 1/2% Subordinated Notes. The estimated fair value of the Three-Year Interest Make-Whole feature is carried in the condensed consolidated balance sheets under “Derivative liability related to convertible subordinated notes” and is being adjusted to its fair value on a quarterly basis until it expires or is paid. Quarterly adjustments to the fair value of the Three-Year Interest Make-Whole are charged to “Derivative (losses) income related to convertible subordinated notes” in the condensed consolidated statements of operations.

During the three and nine months ended December 31, 2004, the Company recorded losses of approximately $0.3 million and income of $2.3 million, respectively, in the condensed consolidated statements of operations for changes in the estimated value of the feature after issuance. The recorded value of the derivative liability related to the 2 1/2% Subordinated Notes (approximately $2.3 million at December 31, 2004) can fluctuate significantly based on fluctuations in the market value of the Company’s common stock.

Warrants — The Company recorded net gains of approximately $0.1 million and net charges of approximately $0.7 million in the three and nine months ended December 31, 2004, respectively, and net charges of $0.7 million and net gains of $1.8 million in the three and nine months ended December 31, 2003, respectively, in “Other income (expense), net” in the condensed consolidated statements of operations in connection with the changes in the fair value of warrants held by the Company which were granted in connection with licensing arrangements. The recorded value of such warrants can fluctuate significantly based on fluctuations in the market value of the underlying securities of the issuer of the warrants. At December 31, 2004, the warrants had a fair value of approximately $2.2 million and were recorded under the caption “Other assets” in the condensed consolidated balance sheets.

8. LITIGATION

Beginning in October 2003, the Company and certain of its current and former officers and directors were named as defendants in six purported securities class action lawsuits filed in the United States District Court for the District of Massachusetts. The cases were captioned: Bennett v. Alkermes, Inc., et. al., 1:03-CV-12091 (D. Mass.); Ragosta v. Alkermes, Inc., et. al., 1:03-CV-12184 (D. Mass.); Barry Family LP v. Alkermes, Inc., et. al., 1:03-CV-12243 (D. Mass.); Waltzer v. Alkermes, Inc., et. al., 1:03-CV-12277 (D. Mass.); Folkerts v. Alkermes, Inc., et. al., 1:03-CV-12386 (D. Mass.); and Slavas v. Alkermes, Inc., et. al., 1:03-CV-12471 (D. Mass.). On May 14, 2004, the six actions were consolidated into a single action captioned: In re Alkermes Securities Litigation, Civil Action No. 03-CV-12091-RCL (D. Mass.). On July 12, 2004, a single consolidated amended complaint was filed on behalf of purchasers of the Company’s common stock during the period April 22, 1999 to July 1, 2002. The consolidated amended complaint generally alleges, among other things, that, during such period, the defendants made misstatements to the investing public relating to the manufacture and FDA approval of the Company’s Risperdal Consta product. The consolidated amended complaint seeks unspecified damages. On September 10, 2004, the Company and the individual defendants filed a motion to dismiss all claims asserted against them in the consolidated amended complaint in their entirety. The Court heard oral argument on the motion on January 12, 2005, and the Company is awaiting a decision on the motion. Although the Company believes these allegations are without merit and intends to vigorously defend against them, the litigation process is inherently uncertain and there can be no guarantee as to the ultimate outcome of these matters.

10

From time to time, we may be subject to other legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

9. TERM LOAN AND COMMITMENT FOR EQUIPMENT FINANCING

On December 22, 2004, the Company entered into a term loan in the principal amount of $3.7 million with General Electric Capital Corporation (“GE”). The term loan is secured by certain of the Company’s equipment pursuant to a security agreement and is subject to an ongoing financial covenant. The loan is payable in 36 monthly installments with the final installment due on December 27, 2007 and bears a floating interest rate equal to the one-month London Interbank Offered Rate (“LIBOR”), which is determined monthly, plus a certain fixed interest rate. The Company may prepay the term loan without any penalty, contingent on GE’s approval, and further use the $3.7 million of available credit to finance new equipment purchases with the same terms and conditions as noted below. If the Company fails to pay any amounts when due, or is in default under or fails to perform any term or condition of the security agreement, then GE may elect to accelerate the entire outstanding principal amount of the loan with accrued interest such that the amounts are immediately due and payable from the Company to GE. In addition, all amounts accelerated shall bear interest at 18% until such amounts are paid in full. As of December 31, 2004, $3.7 million was outstanding under the term loan.

In addition, on December 22, 2004, the Company entered into a commitment for equipment financing with GE. The equipment financing will further require an amendment to an existing Master Lease Agreement dated as of October 16, 2002, as amended by an amendment dated November 7, 2002, by and between the Company and GE. The equipment financing, in the form of an equipment lease line, provides the Company the ability to finance up to $18.3 million in new equipment purchases through December 31, 2005. The equipment financing would be secured by the purchased equipment and will be subject to a financial covenant. The lease terms would provide the Company with the option at the end of the lease to (a) purchase the equipment from GE at the then prevailing market value, (b) renew the lease at a fair market rental value, subject to remaining economic useful life requirements, or (c) return of the equipment to GE, subject to certain conditions. As of December 31, 2004, there were no amounts outstanding under this commitment.

10. SUBSEQUENT EVENT

On February 1, 2005, ACT II, pursuant to the terms of a purchase and sale agreement, sold, assigned and contributed to Royalty Sub the rights of ACT II to collect certain royalty payments and manufacturing fees (the “Royalty Payments”) payable to ACT II under the Janssen Agreements (defined below) and certain agreements that may arise in the future, in exchange for approximately $145 million in cash. The Royalty Payments arise under (i) the license agreements dated February 13, 1996 for the United States and its territories and February 21, 1996 for all countries other than the United States and its territories, by and between ACT II and Janssen Pharmaceutica Inc. and certain of its affiliated entities (“JP”) and (ii) the Manufacturing and Supply Agreement dated August 6, 1997 by and between JPI Pharmaceutica International (“JPI” and together with JP, “Janssen”), JP and ACT II (collectively, the “Janssen Agreements”). The assets of Royalty Sub will not be available to satisfy other obligations of Alkermes.

Also on February 1, 2005, Royalty Sub issued an aggregate principal amount of $170 million of its Risperdal Consta® PhaRMA ^SM Secured 7% Notes due 2018 (the “7% Notes”) to certain institutional investors in a private placement and at a discount for net proceeds after transaction expenses of approximately $145 million. The Royalty Payments are the sole source of payment for the 7% Notes. Alkermes will receive all of the Risperdal Consta revenues in excess of interest, premium, if any, and principal payments. Principal on the 7% Notes must be paid in full by the final legal maturity date of January 1, 2018, unless redeemed earlier. Non-payment of principal will not be an event of default prior to January 1, 2018. The annual cash coupon rate is 7% and is payable quarterly, beginning on April 1, 2005, however portions of the

11

principal amount that are not paid off in accordance with the expected principal repayment profile will accrue interest at 9.75%. The yield to maturity on the 7% Notes is 9.75%. Through January 1, 2009, the 7% Note holders will receive only the quarterly cash interest payments. In addition, beginning on April 1, 2009, principal payments will be made to investors, subject to certain conditions. Timing of the principal repayment will be based on the revenues received by Royalty Sub but will occur no earlier than equally over the twelve quarters between April 1, 2009 and January 1, 2012, subject to certain conditions. The 7% Notes, however, may be redeemed at Royalty Sub’s option, subject, in certain circumstances, to the payment of a redemption premium.

12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Alkermes, Inc. (as used in this section, together with our subsidiaries, “us”, “we” or “our”), a Pennsylvania corporation organized in 1987, is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. Our lead commercial product, Risperdal Consta® [(risperidone) long-acting injection], is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a subsidiary of Johnson & Johnson, together with other affiliates (“Janssen”). Our lead proprietary product candidate, Vivitrex^® [(naltrexone) long-acting injection], is a once-a-month injection for the treatment of alcohol dependence. We have a pipeline of extended-release injectable products and pulmonary drug products based on our proprietary technology and expertise, ProLease and Medisorb for extended-release of injectable drug products, and AIR^® for inhaled drug products. Our product development strategy is twofold: we partner our proprietary technology systems and drug delivery expertise with several of the world’s finest pharmaceutical companies and we also develop novel, proprietary drug candidates for our own account. Our headquarters are in Cambridge, Massachusetts, and we operate research and manufacturing facilities in Massachusetts and Ohio. Since our inception in 1987, we have devoted a significant portion of our resources to research and development programs and the purchase of property, plant and equipment. At December 31, 2004, we had an accumulated deficit of approximately $612.6 million.

We have funded our operations primarily through public offerings and private placements of debt and equity securities, bank loans, term loans, equipment financing arrangements and payments under research and development agreements with collaborators. We historically have developed our product candidates in collaboration with others on whom we rely for funding, development, manufacturing and/or marketing. While we continue to develop product candidates in collaboration with others, we also develop proprietary product candidates for our own account that we fund on our own.

Forward-Looking Statements

Any statements herein or otherwise made in writing or orally by us with regard to our expectations as to financial results and other aspects of our business may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning future operating results, the achievement of certain business and operating goals, manufacturing revenues, research and development spending, plans for clinical trials and regulatory approvals, financial goals and projections of capital expenditures, recognition of revenues, restructuring charges in connection with the discontinuation of Nutropin Depot and future financings. These statements relate to our future plans, objectives, expectations and intentions and may be identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “anticipate,” and similar expressions.

Although we believe that our expectations are based on reasonable assumptions within the bounds of our knowledge of our business and operations, the forward-looking statements are neither promises nor guarantees and our business is subject to significant risk and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations. Factors which could cause actual results to differ materially from our expectations set forth in our forward-looking statements include, among others: (i) Risperdal Consta and our product candidates (including our proprietary product candidate, Vivitrex), if approved for marketing, may not be launched successfully in one or all indications for which marketing is approved, and, if launched, may not produce significant revenues; (ii) we rely on our partners to determine the regulatory and marketing strategies for Risperdal Consta and our other partnered programs; (iii) after the completion of clinical trials for our product candidates (including our proprietary product candidate, Vivitrex) and the submission for marketing approval, the FDA or other health authorities could refuse to accept such filings or could request additional preclinical or clinical studies be conducted, each of which could result in significant delays, or such authorities could refuse to approve the product at all; (iv) we may be unable to manufacture Risperdal Consta or to scale-up or manufacture future products, including our proprietary product candidate, Vivitrex, on a commercial scale or economically and in addition, we may be unable to add additional production capacity for Risperdal Consta or unexpected events could interrupt manufacturing operations

13

at our Risperdal Consta facility, which is the sole source of supply for that product; (v) whether additional regulatory approvals will be received or whether commercial launches of Risperdal Consta in countries where it has been or may be approved occur in a timely or successful manner; (vi) Risperdal Consta and our product candidates (including our proprietary product candidate, Vivitrex), in commercial use, may have unintended side effects, adverse reactions or incidents of misuse and the FDA or other health authorities could require post approval studies or require removal of our products from the market; (vii) we may enter into a collaboration with a third party to market or fund a proprietary product candidate, including our proprietary product candidate, Vivitrex, and the terms of such a collaboration may not meet our expectations or the expectations of the financial markets; (viii) our delivery technologies or product development efforts may not produce safe, efficacious or commercially viable products; (ix) our collaborators could elect to terminate or delay programs at any time and disputes with collaborators or failure to negotiate acceptable new collaborative arrangements for our technologies could occur; (x) clinical trials may take more time or consume more resources than initially envisioned; (xi) the risk that results of earlier clinical trials are not necessarily predictive of the safety and efficacy results in larger clinical trials; (xii) our product candidates could be ineffective or unsafe during preclinical studies and clinical trials and we and our collaborators may not be permitted by regulatory authorities to undertake new or additional clinical trials for product candidates incorporating our technologies, or clinical trials could be delayed; (xiii) we may not recoup any of our $100 million investment in Reliant Pharmaceuticals, LLC (“Reliant”); (xiv) the securities litigation brought against us may result in financial losses or require the dedication of significant management resources; (xv) even if our product candidates appear promising at an early stage of development, product candidates could fail to receive necessary regulatory approvals, be difficult to manufacture on a large scale, be uneconomical, fail to achieve market acceptance, be precluded from commercialization by proprietary rights of third parties or experience substantial competition in the marketplace; (xvi) technological change in the biotechnology or pharmaceutical industries could render our product candidates obsolete or noncompetitive; (xvii) difficulties or set-backs in obtaining and enforcing our patents and difficulties with the patent rights of others could occur; (xviii) we may not become profitable and could continue to incur losses for the foreseeable future; and (xix) we may need to raise substantial additional funding to continue research and development programs and clinical trials and could incur difficulties or setbacks in raising such funds.

Critical Accounting Policies

As fully described in the “Management Discussion and Analysis” section of the Company’s Annual Report on Form 10-K for the year ended March 31, 2004, we consider our critical accounting policies to be:

	•	Revenue recognition;
	•	Equity method investment in Reliant Pharmaceuticals, Inc.;
	•	Derivatives embedded in certain debt securities;
	•	Warrant valuations;
	•	Cost of goods manufactured;
	•	Research and development expenses; and
	•	Restructuring.

We recorded restructuring charges in the consolidated statements of operations during the quarter ended June 30, 2004. As discussed below, we now consider our accounting policy on restructuring to be a critical accounting policy.

Restructuring — We recorded restructuring charges in our consolidated statements of operations in August 2002 in connection with a restructuring program to reduce our cost structure as a result of the financial impact of a delay in

14

the U.S. launch of Risperdal Consta by our collaborative partner, Janssen (the “2002 Restructuring”). We also recorded restructuring charges in June 2004 in connection with the decision by Alkermes and Genentech to stop commercialization of Nutropin Depot (the “2004 Restructuring”).

Charges recorded in the condensed consolidated statements of operations in connection with the 2002 Restructuring and the 2004 Restructuring required that management make estimates related to our ability to sublease exited facilities, the rates at which we may be able to sublease exited facilities and the net realizable value of certain fixed assets. See “Results of Operations” below for additional information related to the 2002 Restructuring and the 2004 Restructuring.

Results of Operations

The net loss for the three months ended December 31, 2004 was $9.0 million or $0.10 per basic and diluted share as compared to a net loss of $20.9 million or $0.23 per basic and diluted share for the three months ended December 31, 2003.

The net loss for the nine months ended December 31, 2004 was $59.4 million or $0.66 per basic and diluted share as compared to a net loss of $77.7 million or $0.97 per basic and diluted share for the nine months ended December 30, 2003.

Total revenues were $23.6 million and $53.1 million for the three and nine months ended December 31, 2004, respectively, as compared to $11.2 million and $23.0 million for the three and nine months ended December 31, 2003, respectively.

Total manufacturing and royalty revenues were $16.6 million and $34.5 million for the three months and nine months ended December 31, 2004, respectively, as compared to $8.6 million and $15.5 million for the three and nine months ended December 31, 2003, respectively.

Total manufacturing revenues were $13.9 million and $27.8 million for the three and nine months ended December 31, 2004, respectively, all related to manufacturing of Risperdal Consta. This is compared to $7.5 million and $13.1 million for the three and nine months ended December 31, 2003, respectively, including $7.3 million and $12.5 million, respectively, of manufacturing revenues for Risperdal Consta. The increase in manufacturing revenues for the three and nine months ended December 31, 2004 as compared to the three months ended December 31, 2003 was due to increased shipments of Risperdal Consta to Janssen. Risperdal Consta is marketed in more than 45 countries. Under our manufacturing and supply agreement with Janssen, we earn manufacturing revenues upon shipment of product by Alkermes to Janssen based on a percentage of Janssen’s net selling price. These percentages are based on the volume of units shipped to Janssen in any given calendar year, with a minimum manufacturing fee of 7.5%. We anticipate that we will earn manufacturing revenues at an average of 8.2% of Janssen’s net sales price for Risperdal Consta in the fiscal year ending March 31, 2005 as compared to 9.8% in the fiscal year ended March 31, 2004. As discussed below, in the quarter ended June 30, 2004, we ceased commercial production of Nutropin Depot and there were therefore no manufacturing revenues earned during the three and nine months ended December 31, 2004 related to Nutropin Depot.

Total royalty revenues were $2.7 million and $6.7 million for the three and nine months ended December 31, 2004, respectively, including $2.6 million and $6.5 million, respectively, of royalty revenues for Risperdal Consta. This is compared to $1.1 million and $2.4 million for the three and nine months ended December 31, 2003, respectively, including $0.9 million and $1.8 million, respectively, of royalty revenues from Risperdal Consta. The increase in royalty revenues for the three and nine months ended December 31, 2004 as compared to the same period in 2003 was due to an increase in global sales of Risperdal Consta by Janssen. Under our license agreements with Janssen, we record royalty revenues equal to 2.5% of Janssen’s net sales of Risperdal Consta in the quarter when the product is sold by Janssen.

15

Research and development revenue under collaborative arrangements was $7.0 million and $18.6 million for the three and nine months ended December 31, 2004, respectively. This compares to $2.6 million and $7.5 million for the three and nine months ended December 31, 2003, respectively. The increase in research and development revenue for the three and nine months ended December 31, 2004 as compared to the same period in 2003 was primarily due to revenues earned related to work performed on the Eli Lilly and Company (“Lilly”) AIR insulin and AIR human growth hormone (“hGH”) programs and to work performed on several other collaborative programs. See discussion of the funding of our Lilly development programs in “Liquidity and Capital Resources” below.

Cost of goods manufactured was $4.9 million and $12.6 million for the three and nine months ended December 31, 2004, consisting of approximately $4.9 million and $10.3 million, respectively, for Risperdal Consta and $0 and $2.3 million for Nutropin Depot. Cost of goods manufactured was $4.1 million and $11.2 million for three and nine months ended December 31, 2003, consisting of approximately $2.7 million and $7.5 million, respectively, for Risperdal Consta and $1.4 million and $3.7 million, respectively, for Nutropin Depot. The increase in cost of goods manufactured in the three months ended December 31, 2004 as compared to the same period in 2003 was primarily the result of increased manufacturing volumes of Risperdal Consta as well as a one-time write-off of Nutropin Depot inventory of $1.3 million recorded under the caption “Cost of goods manufactured” in our condensed consolidated statement of operations in the quarter ended June 30, 2004.

Research and development expenses were $20.1 million and $66.8 million for the three and nine months ended December 31, 2004 as compared to $21.1 million and $66.2 million for the three and nine months ended December 30, 2003. Research and development expenses were lower in the three months ended December 30, 2004 as compared to the three months ended December 30, 2003 primarily due to a decrease in external research costs related to the clinical trials of Vivitrex. The increase in research and development expenses for the nine months ended December 30, 2004 as compared to the nine months ended December 30, 2003 was primarily due to increases in personnel costs related to our proprietary and collaborator product candidates and to increases in occupancy costs, partially offset by a decrease in external research costs related to the clinical trials of Vivitrex.

A significant portion of our research and development expenses (including laboratory supplies, travel, dues and subscriptions, recruiting costs, temporary help costs, consulting costs and allocable costs such as occupancy and depreciation) are not tracked by project as they benefit multiple projects or our drug delivery technologies in general. Expenses incurred to purchase specific services from third parties to support our collaborative research and development activities are tracked by project and are reimbursed to us by our partners. We generally bill our partners under collaborative arrangements using a single full-time equivalent or hourly rate. This rate has been established by us based on our annual budget of salaries, employee benefits and the billable non-project-specific costs mentioned above and is generally increased annually based on increases in the consumer price index. Each collaborative partner is billed using a full-time equivalent or hourly rate for the hours worked by our employees on a particular project, plus any direct external research costs. We account for our research and development expenses on a departmental and functional basis in accordance with our budget and management practices.

Below is a summary of our proprietary and collaborators’ commercial products and product candidates and their respective stages of clinical development.

16

In August 2004, we announced that Lilly made a positive product decision to proceed with significant investment for the further development of an inhaled formulation of insulin. The decision follows the successful execution of several critical steps: the completion and analysis of data from a Phase II study; the achievement of commercial manufacturing powder production scale-up; and the development and testing of the commercial pulmonary insulin inhaler system. Development activities will include both clinical trials and additional manufacturing activities for the inhaler system and the production facility.

In October 2004, Alkermes and Serono discontinued development of the sustained-release version of recombinant human follicle stimulating hormone (“r-hFSH”) for the treatment of infertility. Despite positive early-stage clinical trial results, this decision was based on a shift of priorities within Serono.

In November 2004, we, along with partners Amylin Pharmaceuticals, Inc. and Lilly made the decision to initiate a Phase II multi-dose study of exenatide LAR (long-acting release), in type 2 diabetes patients using a once-a-week dosing regimen. Patient screening and enrollment for the Phase II multi-dose study began in January 2005. The study is expected to be completed by early 2006. Data from the ongoing Phase II single-dose study have demonstrated sustained release of exenatide with no dose-limiting effects.

In January 2005, we announced that we will expand production capacity for Risperdal Consta by building a third production line. This expansion at Alkermes’ Wilmington, Ohio, facility is designed to meet anticipated future demand for Risperdal Consta. Under the terms of the agreement with Janssen, we will be responsible for managing the design, engineering, construction, validation and all other aspects of the project based upon a mutually-agreed project plan, and Janssen will reimburse us for such costs incurred in accordance with a mutually agreed upon budget. Upon validation of such facility, Alkermes will be responsible for on-going operating costs.

Sales, general and administrative expenses were $6.9 million and $21.3 million for the three and nine months ended December 31, 2004 as compared to $6.5 million and $18.2 million for the three and nine months ended December 31, 2003. Sales, general and administrative expenses for the three and nine months ended December 31, 2004 were higher than in the three and nine months ended December 31, 2003 primarily as a result of an increase in sales and marketing costs as we prepare for the potential future commercialization of Vivitrex.

In August 2002, we announced a restructuring program to reduce our cost structure as a result of the financial impact of a delay in the U.S. launch of Risperdal Consta by our collaborative partner, Janssen (the “2002 Restructuring”). The restructuring program reduced our workforce by 122 employees, representing 23% of our total workforce at that time, and included consolidation and closure of certain leased facilities in Cambridge, Massachusetts, closure of our medical affairs office in Cambridge, England, write-off of leasehold improvements at leased facilities being vacated and reductions of other expenses. As of December 31, 2004, we had paid in cash or written off an aggregate of approximately $1.6 million in employee separation costs and approximately $4.2 million in facility closure costs in connection with the 2002 Restructuring. The amounts remaining in the 2002 Restructuring accrual at December 31, 2004 related to facility lease costs and are expected to be paid through fiscal 2006.

In June 2004, we announced a restructuring program in connection with the decision by Alkermes and Genentech to discontinue commercialization of Nutropin Depot (the “2004 Restructuring”). The decision was based on the significant resources required by both companies to continue manufacturing and commercializing the product. In connection with this decision, we ceased commercial manufacturing of Nutropin Depot in June 2004, reduced our

17

workforce by 17 employees, representing approximately 3% of our total workforce, and recorded restructuring charges in the quarter ended June 30, 2004 of approximately $11.9 million under the caption “Restructuring” in the consolidated statements of operations. The restructuring charges consisted of approximately $0.2 million in employee separation costs, including severance and related benefits, and approximately $11.7 million in facility closure costs, including fixed asset write-offs and estimates of future lease costs relating to our ability to sublease the exited facility through the end of its lease term, August 2008. In addition to the restructuring charges recorded in the quarter ended June 30, 2004, we also recorded a one-time write-off of Nutropin Depot inventory of approximately $1.3 million, which was recorded under the caption “Cost of goods manufactured” in the consolidated statements of operations.

As of December 31, 2004, we had paid in cash or written off an aggregate of approximately $8.6 million in facility closure costs and $0.1 million in employee separation costs in connection with the 2004 Restructuring. The amounts remaining in the 2004 Restructuring accrual at December 31, 2004 are expected to be paid out through fiscal 2009 and relate primarily to estimates of lease costs associated with the exited facility.

The following table displays the restructuring activities and liability accounts included in accrued restructuring costs:

Interest income was $0.6 million and $1.9 million for the three and nine months ended December 31, 2004 as compared to $1.0 million and $2.6 million for the three and nine months ended December 31, 2003. The decrease for the nine month periods was primarily the result of lower average cash and investment balances held during the nine months ended December 31, 2004 as compared to the nine months ended December 31, 2003.

Other income (expense), net was income of $0.1 million and expense of $ 0.7 million in the three and nine months ended December 31, 2004 as compared to expense of $0.7 million and income of $1.8 million for the three and nine months ended December 31, 2003. Other income (expense), net represents income or expense recognized on the net changes in the fair value of warrants of public companies held by us in connection with collaboration and licensing arrangements, which are recorded as derivatives under the caption “Other assets” in the condensed consolidated balance sheets. The recorded value of such warrants can fluctuate significantly based on fluctuations in the market value of the underlying securities of the issuer of the warrants.

During the three and nine months ended December 31, 2004, we recorded derivative losses of $0.3 million and derivative income of $2.3 million for changes in the estimated value of the Three-Year Interest Make-Whole feature of the 2 1/2% Convertible Subordinated Notes due 2023 (the “2 1/2% Subordinated Notes”). The estimated value of the Three-Year Interest Make-Whole feature is carried in the consolidated balance sheets under the caption “Derivative liability related to convertible notes” and will be adjusted to its fair value on a quarterly basis until it expires or is paid. Quarterly adjustments to the fair value of the Three-Year Interest Make-Whole will be charged to “Derivative income (losses) related to convertible subordinated notes” in the condensed consolidated statements of

18

operations until it is paid out or expires. The recorded value of the derivative liability related to the 2 1/2% Subordinated Notes, approximately $2.3 million, at December 31, 2004, can fluctuate significantly based on fluctuations in the market value of our common stock.

During the three months and nine months ended December 31, 2003, we recorded derivative income of $0.7 million and derivative losses of $4.0 million in the condensed consolidated statements of operations. In June 2003, we announced that we had exercised our automatic conversion right for the 6.52% Senior Notes. In July 2003, upon conversion of the then outstanding 6.52% Senior Notes and payment of the Two-Year Interest Make-Whole, the embedded derivative was settled in full and the balance was reduced to zero.

Interest expense was $1.2 million and $3.5 million for the three and nine months ended December 31, 2004, respectively, as compared to $1.2 million and $5.3 million for the three and nine months ended December 31, 2003. The decrease for the nine months ended December 31, 2004 as compared to the nine months ended December 31, 2004 was primarily the result of a lower interest rate payable on the convertible debt outstanding during the respective periods.

We do not believe that inflation and changing prices have had a material impact on our results of operations.

Liquidity and Capital Resources

Cash and cash equivalents and short-term investments were approximately $78.1 million at December 31, 2004 as compared to $143.9 million at March 31, 2004. The decrease in cash and cash equivalents and short-term investments during the nine months ended December 31, 2004 was primarily a result of cash outflows to fund our operations and to acquire fixed assets.

We invest in cash equivalents, U.S. Government obligations, high-grade corporate notes and commercial paper, with the exception of our $100 million investment in Reliant. Our investment objectives for our investments, other than our investment in Reliant, are, first, to assure liquidity and conservation of capital and, second, to obtain investment income. Investments classified as long-term at December 31, 2004 consist of U.S. Government obligations held as collateral under certain irrevocable standby letters of credit required under certain lease agreements, including the lease for our corporate headquarters.

In August and September 2003, we issued an aggregate of $125.0 million principal amount of 2 1/2% Subordinated Notes. The 2 1/2% Subordinated Notes are convertible into shares of our common stock at a conversion price of $13.85 per share, subject to adjustment in certain events. The 2 1/2% Subordinated Notes bear interest at 2 1/2% per year, payable semiannually on March 1 and September 1, commencing on March 1, 2004 and are subordinated to existing and future senior indebtedness of Alkermes.

We may elect to automatically convert the notes anytime the closing price of our common stock has exceeded 150% of the conversion price ($20.78), for at least 20 trading days during any 30-day trading period. We may redeem some or all of the notes on or after September 6, 2006. Holders of the notes have the right to require us to repurchase some or all of their notes on September 1, 2008, 2013, and 2018 and upon certain events, including a change in control.

If an automatic conversion occurs on or prior to September 1, 2006, we will pay additional interest in cash or, at our option, in common stock, equal to three full years of interest on the converted notes, “Three-Year Interest Make-Whole”, less any interest actually paid or provided for on the notes prior to automatic conversion. If we elect to pay the additional interest in common stock, the shares of common stock will be valued at 97.5% of the average closing price of our common stock for the five trading days immediately preceding the second trading day prior to the conversion date.

In December 2002, we and Lilly expanded the collaboration for the development of inhaled formulations of insulin and hGH based on our AIR pulmonary drug delivery technology. At that time, Lilly purchased $30.0 million of our

19

Convertible Preferred Stock, the proceeds from which represented $25.0 million and $5.0 million in funding for the Lilly insulin and Lilly hGH development programs, respectively, for the period starting January 1, 2003 and into calendar 2004. As a result of this transaction, we did not recognize research and development revenue related to work performed on the Lilly development programs while the proceeds from the sale of the Convertible Preferred Stock were being spent. In addition, the royalty rate payable to us based on revenues of potential inhaled insulin products was increased. Lilly has the right to return the Convertible Preferred Stock to us in exchange for a reduction in this royalty rate back to its original rate. The Convertible Preferred Stock is convertible into our common stock at the market price at the time of conversion at our option or automatically upon the filing of a new drug application with the FDA for a pulmonary insulin product. The collaboration cannot terminate without cause until January 2005. We will register for resale all of our shares of common stock issued upon conversion of the Convertible Preferred Stock.

In December 2003, Lilly made additional payments to us totaling approximately $7.0 million in order to fund an increase in the scope of our joint development programs, $3.0 million of which represented funding for the Lilly insulin development program and the remaining $4.0 million represented funding for the Lilly hGH development program. The $7.0 million payment was recorded as deferred revenue in the consolidated balance sheets in the quarter ended December 31, 2003. When the funding for a program provided for by the proceeds from the sale of Convertible Preferred Stock has been spent, we will begin to recognize revenue on that program as work is performed. As of June 30, 2004, the entire $5.0 million of funding from the Convertible Preferred Stock related to the Lilly hGH program had been spent. As of September 30, 2004, the entire $25.0 million of funding from the Convertible Preferred Stock related to the Lilly insulin program had been spent. Therefore, beginning in the quarter ended June 30, 2004 for the Lilly hGH program and beginning in the quarter ended September 30, 2004 for the Lilly insulin program, we recorded revenue for work performed on the Lilly hGH and Lilly insulin programs in our condensed consolidated statements of operations. As of December 31, 2004, all of the funding was fully earned and there are no amounts recorded as a current liability under the caption of “Deferred revenue” in the condensed consolidated balance sheets.

Under an addendum to our manufacture and supply agreement with Janssen, Janssen is required to pay us certain minimum amounts of manufacturing revenues relating to our sales of Risperdal Consta to Janssen beginning in 2003. The actual amount of such minimum manufacturing revenues will be determined by a formula and is currently estimated to aggregate approximately $150.0 million. As of December 31, 2004, we had recognized approximately $65 million of cumulative manufacturing revenues against the estimated $150.0 million minimum. Janssen’s minimum revenue obligation will be satisfied when Alkermes reaches approximately $150.0 million in cumulative manufacturing revenues earned from sales of Risperdal Consta to Janssen. While the manufacture and supply agreement with Janssen specifies annual minimum revenues expected to be paid to Alkermes over a ten year period beginning in calendar 2003, we expect our annual manufacturing revenues to exceed those annual minimums. In December 2002, Janssen prepaid the first two years of minimum manufacturing revenues to us, totaling $23.9 million and these amounts were recorded as deferred revenue in our consolidated balance sheets. We have assigned and contributed to Royalty Sub the right to all manufacturing fees payable to ACT II under the manufacturing and supply agreement – see Subsequent Event in the notes to the condensed consolidated financial statements. As of December 31, 2004, all of the prepayment was earned and there were no amounts recorded as a current liability under the caption “Deferred revenue” in the condensed consolidated balance sheets.

We do not have any off-balance sheet arrangements, other than operating leases in the ordinary course of business. Capital expenditures were approximately $12.7 million for the nine months ended December 31, 2004, principally reflecting equipment purchases and building expansion and improvements. We expect our capital expenditures to total approximately $25.0 million during fiscal year 2005, primarily to expand our manufacturing infrastructure for Risperdal Consta and Vivitrex in addition to continued improvements to our manufacturing and development facilities in Massachusetts and Ohio. Our capital expenditures for equipment, facilities and building improvements have been financed to date primarily with proceeds from bank loans and the sales of debt and equity securities. Under the provisions of the existing loans, General Electric Capital Corporation (“GE”) and Johnson & Johnson Finance Corporation have security interests in certain of our assets.

20

On December 22, 2004, we entered into a term loan in the principal amount of $3.7 million with GE. The term loan is secured by certain of our equipment pursuant to a security agreement and is subject to an ongoing financial covenant. The loan is payable in 36 monthly installments with the final installment due on December 27, 2007 and bears a floating interest rate equal to the one month London Interbank Offered Rate (“LIBOR”), which is determined monthly, plus a certain fixed interest rate. We may prepay the term loan without any penalty, contingent on GE’s approval, and further use the $3.7 million of available credit to finance new equipment purchases with the same terms and conditions as noted below. If we fail to pay any amounts when due, or is in default under or fails to perform any term or condition of the security agreement, then GE may elect to accelerate the entire outstanding principal amount of the loan with accrued interest such that the amounts are immediately due and payable from us to GE. In addition, all amounts accelerated shall bear interest at 18% until such amounts are paid in full.

Additionally, on December 22, 2004, we entered into a commitment for equipment financing with GE. The equipment financing will further require an amendment to an existing Master Lease Agreement dated as of October 16, 2002, as amended by Amendment dated November 7, 2002, by and between us and GE. The equipment financing, in the form of an equipment lease line, provides us the ability to finance up to $18.3 million in new equipment purchases through December 31, 2005. The equipment financing would be secured by the purchased equipment and will be subject to a financial covenant. The lease terms would provide us with the option at the end of the lease to (a) purchase the equipment from GE at the then prevailing market value, (b) renew the lease at a fair market rental value, subject to remaining economic useful life requirements, or (c) return of the equipment to GE, subject to certain conditions.

In January 2005, we announced that we will expand production capacity for Risperdal Consta by building a third production line. This expansion at our Wilmington, Ohio, facility is designed to meet anticipated future demand for Risperdal Consta. Under the terms of the agreement, we will be responsible for managing the design, engineering, construction, validation and all other aspects of the project based upon a mutually-agreed project plan, and Janssen will reimburse us for such costs incurred in accordance with a mutually agreed upon budget. Upon validation of such facility, Alkermes will be responsible for on-going operating costs.

On February 1, 2005, Alkermes Controlled Therapeutics Inc. II (“ACT II”), a Pennsylvania corporation and wholly-owned subsidiary of Alkermes, Inc., pursuant to the terms of a purchase and sale agreement, sold, assigned and contributed to RC Royalty Sub LLC, a Delaware limited liability company, and wholly-owned subsidiary of ACT II (“Royalty Sub”) the rights of ACT II to collect certain royalty payments and manufacturing fees (the “Royalty Payments”) payable to ACT II under the Janssen Agreements (defined below) and certain agreements that may arise in the future, in exchange for approximately $145 million in cash. The Royalty Payments arise under (i) the license agreements dated February 13, 1996 for the United States and its territories and February 21, 1996 for all countries other than the United States and its territories, by and between ACT II and Janssen Pharmaceutica Inc. and certain of its affiliated entities (“JP”) and (ii) the Manufacturing and Supply Agreement dated August 6, 1997 by and between JPI Pharmaceutica International (“JPI” and together with JP, “Janssen”), JP and ACT II (collectively, the “Janssen Agreements”). The assets of Royalty Sub will not be available to satisfy other obligations of ours.

Also on February 1, 2005, Royalty Sub issued an aggregate principal amount of $170 million of its Risperdal Consta® PhaRMA ^SM Secured 7% Notes due 2018 (the “7% Notes”) to certain institutional investors in a private placement and at a discount for net proceeds after transaction expenses of approximately $145 million. The Royalty Payments are the sole source of payment for the 7% Notes. We will receive all of the Risperdal Consta revenues in excess of interest, premium, if any, and principal payments. Principal on the 7% Notes must be paid in full by the final legal maturity date of January 1, 2018, unless redeemed earlier. Non-payment of principal will not be an event of default prior to January 1, 2018. The annual cash coupon rate is 7% and is payable quarterly, beginning on April 1, 2005, however portions of the principal amount that are not paid off in accordance with the expected principal repayment profile will accrue interest at 9.75%. The yield to maturity on the 7% Notes is 9.75%. Through January 1, 2009, the 7% Note holders will receive only the quarterly cash interest payments. In addition, beginning on April 1, 2009, principal payments will be made to investors, subject to certain conditions. Timing of the principal repayment will be based on the revenues received by Royalty Sub but will occur no earlier than equally over the twelve quarters between April 1, 2009 and

21

January 1, 2012, subject to certain conditions. The 7% Notes, however, may be redeemed at Royalty Sub’s option, subject, in certain circumstances, to the payment of a redemption premium.

The 7% Notes have not been and will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent an applicable exemption from the registration requirements of the Act. A more detailed description of the obligations of Alkermes and Royalty Sub can be found in our Form 8-K, filed with the Securities and Exchange Commission in connection with this transaction.

We will continue to pursue opportunities to obtain additional financing in the future. Such financing may be sought through various sources, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures. The source, timing and availability of any financings will depend on market conditions, interest rates and other factors. Our future capital requirements will also depend on many factors, including continued scientific progress in our research and development programs (including our proprietary product candidates), the magnitude of these programs, progress with preclinical testing and clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patent claims, competing technological and market developments, the establishment of additional collaborative arrangements, the cost of manufacturing facilities and of commercialization activities and arrangements and the cost of product in-licensing and any possible acquisitions and, for any future proprietary products, the sales, marketing and promotion expenses associated with marketing products.

We believe that our current cash and cash equivalents and short-term investments combined with anticipated manufacturing and royalty revenues, research and development revenues under collaborative arrangements, the approximately $145 million in net proceeds received from the private placement of the 7% Notes and interest income, will be sufficient to meet out anticipated capital requirements through at least March 31, 2007.

The contractual cash obligations disclosure included in our annual report on Form 10-K for the year ended March 31, 2004 has not materially changed since we filed that report, except for the term loan and purchase obligations as follows:

We may need to raise substantial additional funds for longer-term product development, including development of our proprietary product candidates, regulatory approvals and manufacturing and sales and marketing activities that we might undertake in the future. There can be no assurance that additional funds will be available on favorable terms, if at all. If adequate funds are not available, we may be required to curtail significantly one or more of our research and development programs and/or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, product candidates or future products.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As part of our investment portfolio we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. Our short-term investments and restricted investments consist of U.S. Government obligations, high-grade corporate notes and commercial paper. All of our investments in debt securities are classified as “available-for-sale” and are recorded at fair value. Our investments are subject to interest rate risk, and could decline in value if interest rates increase. Due to the conservative nature of our short-term investments and investments policy we do not believe that we have a material exposure to interest rate risk. Although our

22

investments are subject to credit risk, our investment policies specify credit quality standards for our investments and limit the amount of credit exposure from any single issue, issuer or type of investment.

Our “available-for-sale” investments are sensitive to changes in interest rates. Interest rate changes would result in a change in the net fair value of these financial instruments due to the difference between the market interest rate and the market interest rate at the date of purchase of the financial instrument. A 10% decrease in market interest rates would not result in a material impact on the net fair value of such interest-sensitive financial instruments.

A 10% increase or decrease in market interest rates on our term loan with GE would not result in a material impact on our operations. Since the interest rates on our 2 ¹/2% Subordinated Notes, 3.75% Convertible Subordinated Notes, capital leases and the Notes issued in the private placement in February 2005 are fixed, we are not subject to interest rate risk on these financial instruments.

We hold warrants of public companies received in connection with collaboration and licensing arrangements, which are recorded as derivatives under the caption “Other assets” in the condensed consolidated balance sheets. The recorded value of such warrants, and accordingly our “Other income (expense), net”, can fluctuate significantly based on fluctuations in the market value of the underlying securities of the issuer of the warrants

Foreign Currency Exchange Rate Risk

The royalty revenues we recognize and report in our condensed consolidated statements of operations and the related payments we receive on our Risperdal Consta product are calculated as a percentage of the net sales made by our collaborative partner. Some of these sales made by our collaborative partner are made in foreign countries. These foreign sales are initially denominated in foreign currency in which the sale is made and subsequently converted into U.S. dollars at the then foreign currency spot rate to determine the amount that our collaborative partner pays us as royalties. Fluctuations in the foreign currency exchange ratio between the U.S. dollars and these foreign currencies will have the effect of increasing or decreasing our recognized and reported royalty revenues and the related payments we receive even if there is a constant amount of sales in foreign currencies. For example, if the U.S. dollar strengthens against a foreign currency, then our royalty revenues and related payments will decrease given a constant amount of sales in such foreign currency.

The impact on our royalty revenues and related payment from fluctuations in foreign currency exchange rates is based on a number of factors, including the amount of sales in any foreign currency, the exchange ratio (and the change in the foreign currency exchange ratio from the prior period) between a foreign currency and the U.S. dollar, and the amount of sales by our collaborative partner that are denominated in foreign currencies. We do not currently hedge our foreign currency exchange rate risk.

Item 4. Controls and Procedures

As of December 31, 2004, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(b) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2004, our disclosure controls and procedures were effective in ensuring that material information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, including ensuring that such material information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Beginning in October 2003, we and certain of our current and former officers and directors were named as defendants in six purported securities class action lawsuits filed in the United States District Court for the District of Massachusetts. The cases were captioned: Bennett v. Alkermes, Inc., et. al., 1:03-CV-12091 (D. Mass.); Ragosta v. Alkermes, Inc., et. al., 1:03-CV-12184 (D. Mass.); Barry Family LP v. Alkermes, Inc., et. al., 1:03-CV-12243 (D. Mass.); Waltzer v. Alkermes, Inc., et. al., 1:03-CV-12277 (D. Mass.); Folkerts v. Alkermes, Inc., et. al., 1:03-CV-12386 (D. Mass.); and Slavas v. Alkermes, Inc., et. al., 1:03-CV-12471 (D. Mass.). On May 14, 2004, the six actions were consolidated into a single action captioned: In re Alkermes Securities Litigation, Civil Action No. 03-CV-12091-RCL (D. Mass.). On July 12, 2004, a single consolidated amended complaint was filed on behalf of purchasers of our common stock during the period April 22, 1999 to July 1, 2002. The consolidated amended complaint generally alleges, among other things, that, during such period, the defendants made misstatements to the investing public relating to the manufacture and FDA approval of our Risperdal Consta product. The consolidated amended complaint seeks unspecified damages. On September 10, 2004, we and the individual defendants filed a motion to dismiss all claims asserted against us and them in a consolidated amended complaint in their entirety. The Court heard oral argument on the motion on January 12, 2005, and we are awaiting a decision on the motion. Although we believe these allegations are without merit and intend to vigorously defend against them, the litigation process is inherently uncertain and there can be no guarantee as to the ultimate outcome of these matters.

From time to time, we may be subject to other legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 6. Exhibits and Reports on Form 8-K

     (a) List of Exhibits:

24

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALKERMES, INC. (Registrant)
Date: February 8, 2005	By:	/s/ Richard F. Pops
		Richard F. Pops
		Chief Executive Officer and Director (Principal Executive Officer)

Date: February 8, 2005	By:	/s/ James M. Frates
		James M. Frates
		Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

26

Exhibit Index

27